Formulation Development
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases
Kynexis recently launched with €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures. Kynexis will advance its lead….
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease With clonoSEQ Assay Across BeiGene’s Lymphoid Malignancy Pipeline
Adaptive Biotechnologies Corporation recently announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ assay technology across the company’s…
Imbria Reports Positive Topline Results for IND Ninerafaxstat in Patients With Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc. recently announced positive topline results from the Phase 2 IMPROVE-HCM clinical trial, evaluating ninerafaxstat, a novel cardiac mitotrope and partial fatty acid…
WEBINAR - Enabling Upstream Intensified Bioprocessing
Intensified upstream bioprocesses are being developed to increase productivity while reducing footprint, costs, and timelines for manufacturing. The higher cell densities generated by….
TriSalus Life Sciences Presents Late-Breaking Phase 1 Liver Metastasis Data; Supports Development of Innovative Immuno-oncology Approach for Liver & Pancreas Indications
TriSalus Life Sciences Inc. recently presented additional Phase 1 clinical data during the late-breaker oral presentation session at the Society of Immunotherapy for Cancer (SITC) 2023…
ProQR Strengthens Leading Intellectual Property Estate for ADAR-Mediated RNA Editing
ProQR Therapeutics N.V. recently announced it has further strengthened its leading intellectual property (IP) estate with the issuance of a new patent in the US…
Acumen Pharmaceuticals & Halozyme Enter Global Collaboration & License Agreement to Develop Subcutaneous Formulation of ACU193 With ENHANZE Technology
Acumen Pharmaceuticals, Inc. recently announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics Inc. to provide Acumen access to Halozyme’s ENHANZE drug delivery technology, based on….
Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of Oral GLP-1 Receptor Agonist for Obesity Treatment
Terns Pharmaceuticals, Inc. recently announced the first participant has been dosed in the Phase 1 clinical trial of TERN-601, the Company’s oral small-molecule glucagon-like peptide-1…
Cambrex Announces Sale of Drug Product Business Unit
Cambrex recently completed the sale of its Drug Product Business Unit to Wilmington, DE- based Noramco. Cambrex’s Drug Product business provides….
Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers
Vaxart, Inc. recently announced it has dosed the first subject in its Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate focused…
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting With FDA for Oral APX3330 in Diabetic Retinopathy
Ocuphire Pharma, Inc. recently announced the successful outcome of an End-of-Phase 2 (EOP2) meeting with the US FDA supporting the advancement of oral APX3330 for…
Sitryx Announces Partner Eli Lilly & Company Exercises Option to SIT-011 for Chronic Autoimmune & Inflammatory Diseases
Sitryx Therapeutics recently announced Eli Lilly & Company has exercised its option to progress SIT-011. Lilly will now lead further development and commercialization of the Phase 1 ready….
Tract Bio Announces Publication Highlighting Stem Cell Variants Driving Lung Inflammation in Modulator-Treated Cystic Fibrosis Patients
Tract Bio recently announced the publication of a research article in the American Journal of Respiratory and Critical Care Medicine (AJRCCM) highlighting the stem cell variants…
Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
Ocular Therapeutix, Inc. recently announced it had received written agreement regarding the overall design from the US FDA under a Special Protocol Assessment (SPA) for…
Daré Bioscience Announces Additional Positive Data From Phase 2b Study of Sildenafil Cream in Women & Proposed Endpoints & Patient Population for Phase 3 Program
Daré Bioscience, Inc. and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA-based novel topical drug delivery company, recently announced additional positive findings…
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech, Inc. recently provided an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review…
Sygnature Discovery Invests Millions in Compound Management to Provide Cutting-Edge Hit Finding Capabilities to Pharma & Biotech Customers
Sygnature Discovery has unveiled its latest investment in a state-of-the-art Azenta compound management storage system, which also provides the opportunity to store customer libraries. High-fidelity…
XOMA Earns $5-Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma
XOMA Corporation recently announced it has earned a $5-million milestone related to the US FDA's acceptance of Day One Biopharmaceuticals’ New Drug Application (NDA) for…
PaxMedica Acquires Suramin Research Assets From Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
PaxMedica, Inc. recently announced the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (RLS). These assets were previously dedicated to the study…
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer & Other Solid Tumors With MET Dysregulation
Apollomics Inc. recently announced the addition of two new cohorts in its ongoing global multi-cohort Phase 2 SPARTA study (NCT03175224), which is evaluating vebreltinib (APL-101) in…
